Table 1.

Top five countries, compounds and indications for Managed Access patient requests in 2020 (as of October 30, 2020, total of 7,620 requests)

Countries (number of requests; % of total)	Compounds (number of requests; % of total)	Indications (number of requests; % of total)
Italy (1,157; 15%)	Alpelisib (1,605; 21%)	Coronavirus infection (1,582; 21%)
France (808; 11%)	Ruxolitinib (1,383; 18%)	Metastatic breast cancer (1,285; 17%)
United States (653; 9%)	Canakinumab (661; 9%)	Secondary progressive multiple sclerosis (399; 5%)
Canada (556; 7%)	Dabrafenib/trametinib (488; 6 %)	Graft vs. host disease (391; 5%)
Belgium (399; 5%) Australia (399; 5%)	Clofazimine (470; 6%)	Chronic myeloid leukemia (327; 4%)